MabCure Establishes Belgian Subsidiary and Relocates Headquarters to Belgium
30 Ottobre 2008 - 3:21PM
Marketwired
MabCure Inc. (the "Company" or "MabCure") (OTCBB: MBCI) is pleased
to announce the establishment of MabCure, N.V., a wholly owned
subsidiary in Belgium. The Company's President and Chief Executive
Officer, Dr. Amnon Gonenne, has been appointed Director and Chief
Executive Officer of the Belgian subsidiary. Dr. Elisha Orr, a
cancer researcher and the developer of the Company's antibody
technology, has been appointed Director and Chief Scientific
Officer of the Belgian subsidiary.
The Belgian subsidiary was established in order to accelerate
the development and commercialization of MabCure's proprietary
products for the early detection of cancer with specific antibodies
and for the creation of highly specific therapeutics (antibodies
and novel drugs) against cancer. MabCure N.V. will be eligible to
apply for research grants from the Flemish Government.
The Belgian subsidiary will be located on the Biomed campus of
the University of Hasselt, which is well-known for its biomedical
research activities. In addition to its own R&D program,
MabCure N.V. plans to develop joint projects with the University of
Hasselt, deploying MabCure's technology. MabCure's global
headquarters will be relocated to Hasselt, Belgium as well.
About MabCure
MabCure is a biotechnology company whose vision is to change the
perception of cancer as a largely incurable disease. MabCure owns
proprietary technology for the creation of unique and highly
specific monoclonal antibodies (Mabs) which will be developed as
diagnostic tools, imaging agents and drugs to treat lethal cancers.
MabCure initial goal is to develop its novel Mabs as diagnostic
tools for the detection of Ovarian and Prostate cancers at an early
stage, when these diseases are still localized and highly curable.
For further information visit the Company's website
www.mabcure.com.
This news release contains "forward-looking statements," as that
term is defined in Section 27A of the United States Securities Act
of 1933, as amended, and Section 21E of the United States
Securities Exchange Act of 1934, as amended. Statements in this
news release which are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such
forward-looking statements include, among others, statements as to
the intended uses of the proceeds received from the private
placement.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the change of business focus of the
management of the Company and the inability of the Company to
pursue its current objectives. These forward-looking statements are
made as of the date of this news release and the Company assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Although the Company believes that
the beliefs, plans, expectations and intentions contained in this
news release are reasonable, there can be no assurance those
beliefs, plans, expectations, or intentions will prove to be
accurate. Investors should consider all of the information set
forth herein and should also refer to the risk factors disclosed in
the Company's periodic reports filed from time to time with the
Securities and Exchange Commission and available at
www.sec.gov.
Distributed by Filing Services Canada and retransmitted by
Marketwire
For further information, please contact MabCure Inc. Corporate
Communications 888-399-3989 Email Contact
Grafico Azioni MabCure (CE) (USOTC:MBCI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni MabCure (CE) (USOTC:MBCI)
Storico
Da Giu 2023 a Giu 2024